Literature DB >> 15148584

[Secondary prevention of cardiovascular diseases].

C A Schneider1, E Erdmann.   

Abstract

Secondary prevention includes all measures to lower the risk of a relapse of a specific disease. For secondary prevention of cardiovascular diseases general measures and specific drug therapy are employed, according to the individual risk pattern. Among the general measures cessation of smoking is most important. In addition, an increase in daily exercise, a normalization of body weight and a healthy diet all lower the cardiovascular risk. For most cases secondary prevention includes also specific drug therapies. Aspirin, statins and beta-blockers are the cornerstones of this drug therapy. After myocardial infarction most patients will also benefit from an ACE-inhibitor therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148584     DOI: 10.1007/s00108-004-1221-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  24 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Physical activity and mortality in older men with diagnosed coronary heart disease.

Authors:  S G Wannamethee; A G Shaper; M Walker
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

3.  Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.

Authors:  Frank M Sacks; Andrew M Tonkin; Timothy Craven; Marc A Pfeffer; James Shepherd; Anthony Keech; Curt D Furberg; Eugene Braunwald
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

4.  beta Blockade after myocardial infarction: systematic review and meta regression analysis.

Authors:  N Freemantle; J Cleland; P Young; J Mason; J Harrison
Journal:  BMJ       Date:  1999-06-26

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Physical activity and coronary heart disease in men: The Harvard Alumni Health Study.

Authors:  H D Sesso; R S Paffenbarger; I M Lee
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

7.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.

Authors:  M de Lorgeril; P Salen; J L Martin; I Monjaud; J Delaye; N Mamelle
Journal:  Circulation       Date:  1999-02-16       Impact factor: 29.690

8.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.